Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2

Authors: N Winston West, Aileen Garcia-Vargas, Charles E Chalfant, Margaret A Park

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer. In this study, we examined mechanisms associated with enhancing the activity of lapatinib via combination with other therapies.

Methods

In the present studies, estrogen receptor (ER) positive and ER negative breast cancer cells were genetically manipulated to up- or downregulate eIF2-alpha, its phospho-mutant, Nck1, or Nck2, then treated with OSU-03012, lapatinib or the combination and assayed for cytotoxicity/cytostaticity using clonogenic assays.

Results

Treatment of breast cancer cell lines with lapatinib and OSU-03012 (a small molecule derivative of the Cox-2 inhibitor celecoxib) induced synergistic cytotoxic/cytostatic effects. This combination therapy corresponded to an increase in the phosphorylation of eIF2-α at serine51 and a decrease in Nck1 expression. Ectopic expression of phospho-mutant eIF2-α (Ser51Ala) or downregulation of eIF2-α in addition to downregulation of the eIF2-α kinase PERK inhibited the synergistic and cytotoxic effects. Furthermore, ectopic expression of Nck1, but not Nck2 abolished the decrease in cell viability observed in combination-treated cells. Downregulation of Nck1 failed to “rescue” the ablation of the cytotoxic/cytostatic effects by the phospho-mutant of eIF2-α (Ser51Ala) demonstrating that Nck1 downregulation is upstream of eIF2-α phosphorylation in the anti-survival pathway activated by lapatinib and OSU-03012 treatment. Finally, co-immunoprecipitation assays indicated that eIF2-α dissociates from the Nck1/PP1 complex after OSU-03012 and lapatinib co-treatment.

Conclusions

These data indicate that OSU-03012 and lapatinib co-treatment is an effective combination therapy, which functions to enhance cell killing through the Nck1/eIF2 complex. Hence, this complex is a novel target for the treatment of metastatic breast cancer.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed
2.
Griffiths CL, Olin JL: Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract. 2012, 25 (3): 319-323. 10.1177/0897190012442062.CrossRefPubMed
3.
De Mattos-Arruda L, Cortes J: Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist. 2012, 17 (5): 631-644. 10.1634/theoncologist.2011-0187.CrossRefPubMedPubMedCentral
4.
Mukai H: Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol. 2010, 15 (4): 335-340. 10.1007/s10147-010-0107-0.CrossRefPubMed
5.
Sorkin A, Goh LK: Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2009, 315 (4): 683-696. 10.1016/j.yexcr.2008.07.029.CrossRefPubMed
6.
Burgess AW: EGFR family: Structure physiology signalling and therapeutic targets. Growth Factors. 2008, 26 (5): 263-274. 10.1080/08977190802312844.CrossRefPubMed
7.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007, 1773 (8): 1263-1284. 10.1016/j.bbamcr.2006.10.001.CrossRefPubMed
8.
9.
Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, et al: Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009, 20 (6): 1026-1031. 10.1093/annonc/mdn759.CrossRefPubMed
10.
Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al: Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clin Cancer Res. 2009, 15 (4): 1452-1459. 10.1158/1078-0432.CCR-08-1080.CrossRefPubMed
11.
Chen ST, Thomas S, Gaffney KJ, Louie SG, Petasis NA, Schonthal AH: Cytotoxic effects of celecoxib on raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leuk Res. 2010, 34 (2): 250-253. 10.1016/j.leukres.2009.09.028.CrossRefPubMed
12.
Wang YC, Kulp SK, Wang D, Yang CC, Sargeant AM, Hung JH, et al: Targeting endoplasmic reticulum stress and akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res. 2008, 68 (8): 2820-2830. 10.1158/0008-5472.CAN-07-1336.CrossRefPubMedPubMedCentral
13.
Park MA, Curiel DT, Koumenis C, Graf M, Chen CS, Fisher PB, et al: PERK-dependent regulation of HSP70 expression and the regulation of autophagy. Autophagy. 2008, 4 (3): 364-367.CrossRefPubMed
14.
Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, et al: OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol. 2006, 70 (2): 589-603. 10.1124/mol.106.025007.CrossRefPubMed
15.
Muaddi H, Majumder M, Peidis P, Papadakis AI, Holcik M, Scheuner D, et al: Phosphorylation of eIF2α at Serine 51 Is an Important Determinant of Cell Survival and Adaptation to Glucose Deficiency. Mol Biol Cell. 2010, 21 (18): 3220-3231. 10.1091/mbc.E10-01-0023.CrossRefPubMedPubMedCentral
16.
Teske BF, Wek SA, Bunpo P, Cundiff JK, McClintick JN, Anthony TG, et al: The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Mol Biol Cell. 2011, 22 (22): 4390-4405. 10.1091/mbc.E11-06-0510.CrossRefPubMedPubMedCentral
17.
Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P: OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biol Ther. 2012, 13 (14): 1501-1511. 10.4161/cbt.22275. PMID: 22990204CrossRefPubMedPubMedCentral
18.
Latreille M, Larose L: Nck in a Complex Containing the Catalytic Subunit of Protein Phosphatase 1 Regulates Eukaryotic Initiation Factor 2α Signaling and Cell Survival to Endoplasmic Reticulum Stress. J Biol Chem. 2006, 281 (36): 26633-26644. 10.1074/jbc.M513556200.CrossRefPubMed
19.
Kebache S, Cardin E, Nguyên DT, Chevet E, Larose L: Nck-1 antagonizes the endoplasmic reticulum stress-induced inhibition of translation. J Biol Chem. 2004, 279 (10): 9662-9671. 10.1074/jbc.M310535200.CrossRefPubMed
20.
Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, et al: Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell. 2001, 7 (6): 1153-1163. 10.1016/S1097-2765(01)00264-7.CrossRefPubMed
21.
Guan S, Fan J, Han A, Chen M, Woodley DT, Li W: Non-compensating roles between Nckalpha and Nckbeta in PDGF-BB signaling to promote human dermal fibroblast migration. J Invest Dermatol. 2009, 129 (8): 1909-1920. 10.1038/jid.2008.457.CrossRefPubMed
22.
Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, et al: MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther. 2004, 3 (8): 739-751. 10.4161/cbt.3.8.968.CrossRefPubMed
23.
Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.CrossRefPubMed
24.
Peng X, Jhaveri P, Hussain-Hakimjee EA, Mehta RG: Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB-231 breast cancer cells responsive to 1 alpha-hydroxyvitamin D5. Carcinogenesis. 2007, 28 (5): 1000-1007.CrossRefPubMed
25.
Clinchy B, Gazdar A, Rabinovsky R, Yefenof E, Gordon B, Vitetta ES: The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice. Breast Cancer Res Treat. 2000, 61 (3): 217-228. 10.1023/A:1006494001861.CrossRefPubMed
26.
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10: 515-527. 10.1016/j.ccr.2006.10.008.CrossRefPubMedPubMedCentral
27.
Sanz-Pamplona R, Aragüés R, Driouch K, Martín B, Oliva B, Gil M, et al: Expression of Endoplasmic Reticulum Stress Proteins Is a Candidate Marker of Brain Metastasis in both ErbB-2+ and ErbB-2− Primary Breast Tumors. Am J Pathol. 2011, 179 (2): 564-579. 10.1016/j.ajpath.2011.04.037.CrossRefPubMedPubMedCentral
28.
Sequeira SJ, Ranganathan AC, Adam AP, Iglesias BV, Farias EF, Aguirre-Ghiso JA: Inhibition of proliferation by PERK regulates mammary acinar morphogenesis and tumor formation. PLoS One. 2007, 2 (7): e615-10.1371/journal.pone.0000615.CrossRefPubMedPubMedCentral
29.
Noh EM, Lee YR, Chay KO, Chung EY, Jung SH, Kim JS, Youn HJ: Estrogen receptor α induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells. Mol Med Rep. 2011, 4 (2): 215-219. PMID: 21468554PubMed
30.
Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E: Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 2011 May 27, 286 (21): 19127-19137. 10.1074/jbc.M110.216887. PMID:21471222CrossRefPubMedPubMedCentral
31.
Callans LS, Naama H, Khandelwal M, Plotkin R, Jardines L: Raf-1 protein expression in human breast cancer cells. Ann Surg Oncol. 1995 Jan, 2 (1): 38-42. 10.1007/BF02303700.CrossRefPubMed
32.
Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H: Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol. 2010 Feb, 21 (2): 255-262. 10.1093/annonc/mdp304.CrossRefPubMed
33.
Mounir Z, Krishnamoorthy JL, Robertson GP, Scheuner D, Kaufman RJ, Georgescu MM, et al: Tumor Suppression by PTEN Requires the Activation of the PKR-eIF2{alpha} Phosphorylation Pathway. Sci Signal. 2009, 2 (102): 85-CrossRef
34.
O’Loghlen A, Pérez-Morgado MI, Salinas M, Martín ME: Reversible inhibition of the protein phosphatase 1 by hydrogen peroxide: Potential regulation of eIF2α phosphorylation in differentiated PC12 cells. Arch Biochem Biophys. 2003, 417 (2): 194-202. 10.1016/S0003-9861(03)00368-0.CrossRefPubMed
35.
Kim SH, Forman AP, Mathews MB, Gunnery S: Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene. 2000, 19 (27): 3086-94. 10.1038/sj.onc.1203632.CrossRefPubMed
36.
Eden S, Rohatgi R, Podtelejnikov AV, Mann M, Kirschner MW: Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature. 2002, 418 (6899): 790-793. 10.1038/nature00859.CrossRefPubMed
37.
Huang M, Anand S, Murphy EA, Desgrosellier JS, Stupack DG, Shattil SJ, Schlaepfer DD, Cheresh DA: EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene. 2012, 31 (22): 2783-2793. 10.1038/onc.2011.450.CrossRefPubMed
38.
De Benedetti A, Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004, 23 (18): 3189-3199. 10.1038/sj.onc.1207545.CrossRefPubMed
39.
Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA: Functional coupling of p38-induced Upregulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006, 66: 1702-1711. 10.1158/0008-5472.CAN-05-3092.CrossRefPubMedPubMedCentral
40.
Sharma SV, Settleman J: Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock” Biochem. Pharmacol. 2010, 80 (5): 666-673.
Metadata
Title
OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2
Authors
N Winston West
Aileen Garcia-Vargas
Charles E Chalfant
Margaret A Park
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-256

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Study protocol

A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2gene carriers

Research article

Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer

Research article

ITGA3 and ITGB4 expression biomarkers estimate the risks of locoregional and hematogenous dissemination of oral squamous cell carcinoma

Research article

MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of Delta-like1

Research article

Variants at the 9p21 locus and melanoma risk

Research article

Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits